designed to be used by anyone in the community

ZURNAI delivers 1.5 mg nalmefene base/0.5 mL in a prefilled, single-dose auto-injector.¹

alt here..

Administration instructions

Step-by-step instructions for administering ZURNAI are included on the body of the auto-injector.

Expiration date

Check the expiration date. Replace ZURNAI before the expiration date.

Safety seal

This device includes a safety seal that will break when the cap is removed.

Do not use the device if the safety seal is already broken or missing before use.

Viewing window

Liquid should be clear, colorless to light-yellow and free of particles. You may see air bubbles. This is normal.

Window turns orange when injection is complete.

Needle guard

Reduces chance of accidental needle stick.

Blue cap

Once the safety seal is broken and blue cap is removed, ZURNAI must be used immediately or disposed of properly.

Do not use if safety cap is missing or seal is broken.

Actor portrayals.

how to use ZURNAI²

Refer to for additional administration details.

ZURNAI is designed to be used by anyone in the community—from first responders to family members.
Instruct patients and their family members or caregivers to become familiar with all information contained in the carton as soon as they receive ZURNAI.

1

Twist blue cap and
then pull

Illustration of two hands twisting and pulling the cap off the auto-injector

2

Push needle end into outer thigh until click— then hold for 3 seconds

Illustration of a man administering the auto-injector into a person's thigh

3

Injection complete when window is orange

Illustration of the window of the auto-injector turning orange

4

Call 911 and watch the person. Stay until the ambulance arrives

Illustration of a man kneeling beside an unconscious man

!

If the person does not wake up within 2–5 minutes after injection, repeat steps 1–3 with a new ZURNAI Auto-Injector.¹

!

Always seek emergency medical assistance after administration of the first dose of ZURNAI in the event of a suspected, potentially life-threatening opioid emergency.¹

DID YOU KNOW?

ZURNAI can be administered
through clothing.¹

ZURNAI auto-injector carton and ZURNAI auto-injector with the instructions for use printed on the side

Not actual size.

Continue exploring

Actor portrayals.

Opioid overdose crisis

Indications and Usage

ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.

ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present.

ZURNAI is not a substitute for emergency medical care.

Important Safety Information and Indications and Usage

CONTRAINDICATIONS

ZURNAI is contraindicated in patients known to be hypersensitive to nalmefene hydrochloride or to any other ingredients in the product.

WARNINGS AND PRECAUTIONS

Risk of Recurrent Respiratory and Central Nervous System Depression

A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI if necessary, using a new auto-injector with each dose while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonist/Antagonists

Reversal of respiratory depression by partial agonists or mixed agonists/antagonists such as buprenorphine and pentazocine, may be incomplete. Repeat doses of ZURNAI may be required.

Precipitation of Severe Opioid Withdrawal

The use of ZURNAI in patients who are opioid dependent may precipitate opioid withdrawal.

Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular (CV) effects. These events have primarily occurred in patients who had preexisting CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of ZURNAI.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include the following signs and symptoms: convulsions, excessive crying, and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal.

Risk of Opioid Overdose from Attempts to Overcome the Blockade

Attempts to overcome opioid withdrawal symptoms caused by opioid antagonists with high or repeated doses of exogenous opioids may lead to opioid intoxication and death.

ADVERSE REACTIONS

Most common adverse reactions (> 5%) are feeling hot, nausea, headache, dizziness, chills, vomiting, allodynia, palpitations, tinnitus, ear discomfort, feeling abnormal, burning sensation, hot flush, and irritability.

USE IN SPECIFIC POPULATIONS

Pregnancy

An opioid overdose is a medical emergency and can be fatal for the pregnant woman and fetus if left untreated. Treatment with ZURNAI for opioid overdose should not be withheld because of potential concerns regarding the effects of ZURNAI in the fetus.

Pediatric Use

The safety and effectiveness of ZURNAI for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, have not been established in pediatric patients younger than 12 years of age.

Geriatric Use

Clinical studies of nalmefene hydrochloride injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Please read

To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma L.P. at 1 888-726-7535, option 2, or FDA at 1-800-FDA-1088 or .

Intended for healthcare professionals of the United States of America only.

References: 1. ZURNAI™ (nalmefene injection) Auto-Injector Full Prescribing Information. Purdue Pharma L.P.; 2024. 2. ZURNAI™ (nalmefene injection) Auto-Injector Instructions for Use. Purdue Pharma L.P.; 2024.